Division of Cancer Epidemiology and Genetics, NCI, NIH, DHHS, Bethesda, Maryland.
Regional Laboratory, Kaiser Permanente Northern California, Berkeley, California.
Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.
Cervical intraepithelial neoplasia grade 2 (CIN2) frequently regresses, is typically slow-growing, and rarely progresses to cancer. Some women forgo immediate treatment, opting for conservative management (heightened surveillance with cytology and colposcopy), to minimize overtreatment and increased risk of obstetric complications; however, there are limited data examining clinical outcomes in these women. We performed a retrospective cohort analysis of younger women diagnosed with initially untreated CIN1/2, CIN2 and CIN2/3 lesions at Kaiser Permanente Northern California between 2003 and 2015. Clinical outcomes were categorized into five mutually exclusive hierarchical groups: cancer, treated, returned to routine screening, persistent high-grade lesion, or persistent low-grade lesion. Median follow-up for the 2,417 women was 48 months. Six women were diagnosed with cancer (0.2%), all with history of high-grade cytology, and none after a negative cotest. Thirty percent of women were treated, and only 20% returned to routine screening; 50% remained in continued intensive follow-up, of which 86% had either low-grade cytology/histology or high-risk human papillomavirus (HPV) positivity, but not necessarily persistence of a single HPV type. No cancers were detected after a single negative cotest in follow-up. Almost half of initially untreated women did not undergo treatment, but remained by protocol in colposcopy clinic for 2 or more years in the absence of persisting CIN2 Their incomplete return to total negativity was possibly due to sequential new and unrelated low-grade abnormalities. The prolonged colposcopic surveillance currently required to return to routine screening in the absence of persisting CIN2 might not be necessary after a negative cotest. Many younger women under conservative management following an initial CIN2 result remain in a clinical protocol of prolonged intensified surveillance without a subsequent diagnosis of CIN2 or more severe diagnoses. More research is needed to determine whether such prolonged management might be unnecessary following a negative cotest for those women with an initial CIN2 but otherwise only low-grade findings. .
宫颈上皮内瘤变 2 级(CIN2)常自行消退,生长缓慢,很少进展为癌症。一些女性选择放弃立即治疗,选择保守治疗(细胞学和阴道镜检查的加强监测),以尽量减少过度治疗和产科并发症的风险;然而,目前关于这些女性的临床结局的研究数据有限。我们对 2003 年至 2015 年期间在 Kaiser Permanente 北加州接受初始未治疗的 CIN1/2、CIN2 和 CIN2/3 病变诊断的年轻女性进行了回顾性队列分析。临床结局分为五个相互排斥的层次组:癌症、治疗、恢复常规筛查、持续性高级别病变或持续性低级别病变。2417 名女性的中位随访时间为 48 个月。6 名女性被诊断为癌症(0.2%),均有高级别细胞学病史,且无一例在阴性 cotest 后发生。30%的女性接受了治疗,只有 20%的女性恢复了常规筛查;50%的女性仍在持续强化随访中,其中 86%的女性细胞学/组织学为低级别或高危型人乳头瘤病毒(HPV)阳性,但不一定持续存在单一 HPV 类型。在后续随访中,单次阴性 cotest 后未发现癌症。近一半的初始未治疗女性未接受治疗,但根据协议在阴道镜检查诊所中持续随访 2 年以上,且无持续性 CIN2。她们未能完全恢复全阴性可能是由于连续出现新的、无关的低级别异常。在没有持续性 CIN2 的情况下,目前为恢复常规筛查而需要进行的长时间阴道镜检查可能在阴性 cotest 后不必要。许多在初始 CIN2 结果后接受保守治疗的年轻女性仍处于延长强化监测的临床方案中,而没有后续诊断为 CIN2 或更严重的诊断。需要更多的研究来确定对于那些初始 CIN2 但仅为低级别病变的女性,在阴性 cotest 后是否不需要如此长时间的管理。